veronapharma.com - VRNA Company profit before taxes, interest and amortization
This chart on GURU.Markets displays the absolute EBITDA volume for Verona Pharma plc (VRNA), where the mark indicates the current profit level. David Zaccardi's team is currently adapting the business to market realities. The launch of an innovative COPD drug ensures stability by generating high-margin earnings. The commercialization of Ohtuvayre and the probability of an acquisition by a corporate behemoth are driving growth.
Verona Pharma - analytical breakdowns and key metrics (VRNA)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Verona Pharma plc|VRNA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Verona Pharma PLC|VRNA - Company Aggregate Debts|Debts to Book Value Verona Pharma|VRNA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Verona Pharma|Immediate Liquidity veronapharma.com
- earnings and market ratios statistics:
VRNA - Company Net Income|Net Profit Forecast Verona Pharma plc|VRNA - P/E Multiple|Forward P/E Multiple veronapharma.com|VRNA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Verona Pharma|VRNA - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Verona Pharma|VRNA - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months veronapharma.com|VRNA - Earnings growth in current year|Earnings growth forecast for next year Verona Pharma plc
Summary company analytics:Verona Pharma plc
Long-term asset screening requires strict monitoring of a business's ability to generate cash flow. This indicator measures operating profit before depreciation and amortization, demonstrating the real efficiency of core production without accounting for debt load and taxes. For Verona Pharma plc (VRNA), this metric reflects the financial impact of synergies with global partners in the development of respiratory drugs. Analyzing absolute operating profit allows for an assessment of the company's resilience to costs. The trend in absolute operating profit reveals risks of capital freezing during periods of price stagnation.
Competitors of Verona Pharma plc (VRNA)
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|jyongbio.com - Company profit before taxes, interest and amortization|LGND: Operating profit EBITDA|Amneal Pharmaceuticals, Inc. - Income before deduction of interest, taxes and amortization|PRGO (Perrigo Company) - Operating profit EBITDA|Profit before interest, taxes and amortization Alvotech Biopharmaceuticals ALVO|Profit before payment of interest, taxes and amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Income before deduction of interest, taxes and amortization|ANI Pharmaceuticals, Inc. - Operating profit before deduction of amortization|MannKind Corp - Profit before payment of interest, taxes and amortization|Amphastar - Operating profit EBITDA|Profit before interest, taxes and amortization Pacira Corp|ARS Pharmaceuticals (SPRY) - Profit before payment of interest, taxes and amortization|theravance.com - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Aquestive Therapeutics, Inc.|Profit before interest, taxes and amortization scPharma SCPH|Profit before payment of interest, taxes and amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding - Operating profit before amortization|Operating profit EBITDA SXTC (China SXT Pharmaceuticals, Inc.)|Operating profit EBITDA Eupraxia Pharmaceuticals, Inc. EPRX|BHST: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization EXOZ (Invizyne Technologies)|oramed.com (ORMP) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization ENTX (Entera Bio)|HYFT (MindWalk Holdings) - Operating profit EBITDA|ABVC: Income before deduction of interest, taxes and amortization|Operating profit EBITDA CPIX|Operating profit EBITDA Quantum BioPharma Ltd. (QNTM)|Profit before payment of interest, taxes and amortization FibroGen Corp FGEN|Income before deduction of interest, taxes and amortization TELO|RANI - Profit before payment of interest, taxes and amortization|Synergy CHC Corp (SNYR) - Operating profit before deduction of amortization|RLYB: Operating profit EBITDA|Lexaria Bioscience Corp. (LEXX) - Operating profit EBITDA|Operating profit before deduction of amortization PULM|PTHL: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Aptorum Group Limited (APM)|LYRA: Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Impact BioMedical IBO|TNF Pharmaceuticals Inc. - Profit before payment of interest, taxes and amortization|cbdMD Corp - Operating profit EBITDA|PainReform Corp (PRFX) - Operating profit before deduction of amortization|CYTO (altamiratherapeutics.com) - Operating profit before deduction of amortization|LIPO (lipella.com) - Profit before payment of interest, taxes and amortization|Profit before payment of interest, taxes and amortization OptiNose|PIRS: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Procaps Group SA (PROC)|Petros Pharma - Operating profit before amortization|Operating profit EBITDA QLI (Qilian International)|Operating profit EBITDA acelyrin.com SLRN|TFFP - Profit before payment of interest, taxes and amortization
